LP
BMRN icon

LMR Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

LMR Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-225,000
Closed -$18.5M – 1309
2024
Q2 		$18.5M Sell
225,000
-55,000
-20% -$4.58M 0.16% 123
2024
Q1 		$24.5M Buy
280,000
+45,000
+19% +$4.03M 0.25% 83
2023
Q4 		$22.7M Buy
235,000
+125,000
+114% +$11.1M 0.26% 93
2023
Q3 		$9.73M Hold
110,000
– – 0.11% 191
2023
Q2 		$9.53M Buy
+110,000
New +$10.4M 0.11% 196

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LMR Partners's BMRN Position: Q2 2026 in Review

LMR Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 324,939 shares — an estimated $18.4M sold.

LMR Partners first reported a position in BMRN in Q3 2019 and held it in 19 quarters. The position peaked at $18.4M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • LMR Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LMR Partners sold 324,939 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $18.4M.
  • LMR Partners first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 19 quarters.
  • LMR Partners's BioMarin Pharmaceuticals position peaked at $18.4M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.